Risk stratification and prognosis determination using (18)F-FDG PET imaging in endometrial cancer patients: a systematic review and meta-analysis

Gynecol Oncol. 2014 Mar;132(3):669-76. doi: 10.1016/j.ygyno.2014.01.039. Epub 2014 Jan 25.


Objectives: In the current study, we systematically searched and analyzed the available literature on the prognostic value of semi-quantitative (18)F-FDG PET imaging (SUVmax/mean) in patients with endometrial cancer and presenting the results in a meta-analytic format.

Methods: Pubmed, SCOPUS, and ISI Web of Knowledge were searched using "endometr* AND PET" as the search algorithm. All studies evaluating the (18)F-FDG PET performance in pre-operative risk stratification or its prognostic value in patients with endometrial cancer were included. Statistical pooling of diagnostic accuracy indices was performed using random effects model. Cochrane Q test and I(2) index were used for heterogeneity evaluation.

Results: Ten studies (771 patients) were included in the systematic review. Pooled average SUVmax values in patients with risk factors [grade III, lymphovascular invasion (LVI), cervical invasion (CI), myometrial invasion (MI)≥50%] were statistically higher than those in patients without risk factors. Pooled HR of pre-operative SUVmax for disease free survival was 7.415 [2.892-19.432] (p=0.000046).

Conclusion: Despite higher average SUVmax in the high-risk group compared to the low-risk group of patients with endometrial cancer, the usefulness of (18)F-FDG PET SUVmax in classifying patients into pre-defined risk groups seems to be limited. However, pre-operative SUVmax of endometrial tumors seems to be an independent prognostic marker of recurrence and death. Further large multicenter studies with adequate follow-up are needed to confirm our findings.

Keywords: (18)F-FDG PET; Endometrial cancer; Meta-analysis; Prognosis; SUVmax; Systematic review.

Publication types

  • Meta-Analysis
  • Research Support, Non-U.S. Gov't
  • Review
  • Systematic Review

MeSH terms

  • Endometrial Neoplasms / diagnosis
  • Endometrial Neoplasms / diagnostic imaging*
  • Female
  • Fluorodeoxyglucose F18*
  • Humans
  • Positron-Emission Tomography
  • Prognosis
  • Radiopharmaceuticals*
  • Risk Factors


  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18